Novartis pays big fine for bribing doctors in the US
The Novartis offices in Basel, Switzerland.
Keystone / Georgios Kefalas
Swiss pharma company Novartis will pay $729 million (CHF688 million) to US authorities in an out-of-court settlement over various charges, including that the company bribed doctors to use its drugs.
This content was published on
2 minutes
Keystone-SDA/dos
Audrey Strauss, the acting Manhattan US Attorney, said the firm had paid out for “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.”
Essentially, Novartis admitted to having organised thousands of lavish conferences and events ostensibly aimed at “further education”. Guest speakers were paid large amounts to attend.
In return, the doctors were incentivised to prescribe Novartis products, such as drugs for high blood pressure and diabetes, which were then reimbursed by state health authorities.
“Not only did Novartis incentivise doctors to host these speaking events, reps bribed the doctors to write more prescriptions of the company’s drugs to give Novartis an advantage over competitors within their field,” said William F Sweeney Jr, head of New York’s FBI office.
“Greed replaced the responsibility the public expects from those who practice medicine.”
As part of the agreement with US authorities, Novartis has signed a five-year code of good conduct. The Basel-based firm also said on Thursday that it was revising its methods of providing medical training, notably by planning more online webinars.
In a statement, Novartis CEO Vas Narasimhan said that the company had already changed (the charges in question were raised by a whistle-blower in 2011) and that it had “new leadership, a stronger culture, and a more comprehensive commitment to ethics”.
“With these agreements we mark an important milestone on our journey to build trust with society as we continue re-imagining medicine to improve and extend lives all around the world,” Narasimhan said.
A week ago Novartis and two of its subsidiaries admitted to further bribery schemes involving dealings in Vietnam and Greece, and agreed to pay some $347 million to settle US investigations.
As of Thursday, the stock market has not reacted particularly strongly: the Novartis share price dropped 0.8%, around the same as its competitor Roche.
Popular Stories
More
Life & Aging
Switzerland no longer wants to foot the bill for ‘suicide tourism’
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Swiss organisations unhappy with species protection funding
This content was published on
Swiss environmental organisations consider the financing plan adopted at the World Conference on Nature in Rome to be inadequate.
Swiss researchers make progress on malaria vaccine
This content was published on
A Swiss research team has come one step closer to developing an effective malaria vaccine. They have genetically modified the malaria parasite so that it cannot cause malaria.
Peace Prize launched to mark centenary of Locarno Treaties
This content was published on
To mark the 100th anniversary of the Locarno Treaties, the Swiss city of Locarno has launched a Peace Prize in collaboration with the Locarno Film Festival. This will be presented for the first time in August.
Swiss-built robot changes shape to adapt to terrain
This content was published on
Scientists at the Swiss Federal Institute of Technology Lausanne (EPFL) have developed a bioinspired robot capable of changing shape according to its environment.
US-EU trade dispute will have no impact on Switzerland, says Swiss president
This content was published on
Switzerland will not suffer from the consequences of the looming trade dispute between the US and the EU, according to Karin Keller-Sutter.
US ends funding for four Swiss-run children’s aid projects
This content was published on
The United States has definitively ended its funding for four projects run by the children's aid organisation Terre des hommes.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
US Senate asks Novartis to shed light on data manipulation allegations
This content was published on
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma.
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.